AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9599499 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 45
Study 8025768 — intervention group
Group type: EXPERIMENTAL
Intervention: UK,74505 25 mg
Number of subjects: 12
Study 8025768 — intervention group
Group type: EXPERIMENTAL
Intervention: UK,74505 100 mg
Number of subjects: 12
Study 8025768 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 2663343 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐mono‐hydroxyethylrutoside
Number of subjects: 105
Study 2663343 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐mono‐hydroxyethylrutoside and acetylsalicylic acid combination
Number of subjects: 105
Study 2663343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 31623762 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarms ON
Number of subjects: 907
Study 31623762 — intervention group
Group type: COMPARATOR
Intervention: Alarms OFF
Number of subjects: 907
Study 28658484 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysyllable Preschool Test
Number of subjects: 93
Study 28658484 — intervention group
Group type: EXPERIMENTAL
Intervention: Print knowledge tasks
Number of subjects: 93
Study 28658484 — intervention group
Group type: EXPERIMENTAL
Intervention: Low polysyllable accuracy and poor phonological processing
Number of subjects: 93
Study 25074354 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive conjoint analysis (ACA) tool
Number of subjects: 374
Study 25074354 — intervention group
Group type: COMPARATOR
Intervention: Usual counseling
Number of subjects: 374
Study 25074354 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive conjoint analysis (ACA) tool (in subgroup analysis)
Number of subjects: 374
Study 25074354 — intervention group
Group type: COMPARATOR
Intervention: Usual counseling (in subgroup analysis)
Number of subjects: 374
Study 23313654 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap-IPV and inactivated influenza vaccine administered concomitantly (Group 1)
Number of subjects: 954
Study 23313654 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza vaccine then Tdap-IPV 28‐35 days later (Group 2)
Number of subjects: 954
Study 23313654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 954
Study 20822814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 30
Study 20822814 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 30
Study 18821365 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT+EMDR
Number of subjects: 43
Study 18821365 — intervention group
Group type: COMPARATOR
Intervention: SRT
Number of subjects: 43
Study 16468062 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (NAL) 0.1 mg kg(‐1)
Number of subjects: 15
Study 16468062 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (SAL)
Number of subjects: 15
Study 16468062 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (NAL)
Number of subjects: 15
Study 12827024 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study 12827024 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0
Study 12827024 — intervention group
Group type: COMPARATOR
Intervention: Control (without perindopril and candesartan)
Number of subjects: 0
Study 10984015 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl starch (ACS) 6%
Number of subjects: 32
Study 10984015 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES) 6%
Number of subjects: 32
Study 9373790 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemotherapy using implanted reservoirs (Epirubicin 40 mg/m2 every month)
Number of subjects: 20
Study 9373790 — intervention group
Group type: COMPARATOR
Intervention: Conventional transcatheter arterial chemotherapy (Epirubicin 60 mg/m2 every 3 months)
Number of subjects: 20
Study 1492848 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine maleate 50 mg
Number of subjects: 4
Study 1492848 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine maleate 100 mg
Number of subjects: 4
Study 1492848 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine maleate 200 mg
Number of subjects: 4
Study 1492848 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine maleate 300 mg
Number of subjects: 4
Study 28698230 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (CE) with methylene blue 0.1%
Number of subjects: 131
Study 28698230 — intervention group
Group type: COMPARATOR
Intervention: Narrow band imaging (NBI)
Number of subjects: 131
Study 26992106 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg plus standard therapy
Number of subjects: 1125
Study 26992106 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard therapy
Number of subjects: 1125
Study 23765238 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine chemotherapy (800 mg/m2 biweekly for major hepatectomy or 1000 mg/m2 in 3 weekly infusions with a 1-week pause for others)
Number of subjects: 198
Study 23765238 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine chemotherapy
Number of subjects: 198
Study 22836057 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose radiation therapy (6.0 Gy in 6 fractions of 1.0 Gy twice weekly)
Number of subjects: 62
Study 22836057 — intervention group
Group type: COMPARATOR
Intervention: Low dose radiation therapy (0.6 Gy in 6 fractions of 0.1 Gy twice weekly)
Number of subjects: 62
Study 22836057 — intervention group
Group type: EXPERIMENTAL
Intervention: Reirradiation (standard dosage) offered to patients with insufficient pain relief after 3 months
Number of subjects: 62
Study 22836057 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with favorable results after 3 months
Number of subjects: 62
Study 19847404 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior-posterior mini-incision instrumentation (Group B)
Number of subjects: 108
Study 19847404 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps sparing side‐cutting instrumentation (Group A)
Number of subjects: 108
Study 19847404 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with computer-assistance)
Number of subjects: 108
Study 17988236 — intervention group
Group type: EXPERIMENTAL
Intervention: Predocol 40 mg/day
Number of subjects: 181
Study 17988236 — intervention group
Group type: EXPERIMENTAL
Intervention: Predocol 60 mg/day
Number of subjects: 181
Study 17988236 — intervention group
Group type: COMPARATOR
Intervention: Tapering prednisolone
Number of subjects: 181
Study 15837945 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan treatment
Number of subjects: 9079
Study 15837945 — intervention group
Group type: COMPARATOR
Intervention: Atenolol treatment
Number of subjects: 9079
Study 12028242 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (37.5 to 225 mg/day)
Number of subjects: 1839
Study 12028242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1839
Study 12028242 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 1839
Study 10628598 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-directed sedation (n = 162)
Number of subjects: 321
Study 10628598 — intervention group
Group type: COMPARATOR
Intervention: Non-protocol-directed sedation (n = 159)
Number of subjects: 321
Study 10628598 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-directed sedation (n = 66)
Number of subjects: 321
Study 10628598 — intervention group
Group type: COMPARATOR
Intervention: Non-protocol-directed sedation (n = 66)
Number of subjects: 321
Study 7746398 — intervention group
Group type: EXPERIMENTAL
Intervention: Detrimental drug group (n = 37)
Number of subjects: 96
Study 7746398 — intervention group
Group type: COMPARATOR
Intervention: Neutral drug group (n = 59)
Number of subjects: 96
Study 7746398 — intervention group
Group type: EXPERIMENTAL
Intervention: Detrimental drug group
Number of subjects: 96
Study 7746398 — intervention group
Group type: COMPARATOR
Intervention: Neutral drug group
Number of subjects: 96
Study 1786954 — intervention group
Group type: EXPERIMENTAL
Intervention: Superoxide dismutase (SOD)
Number of subjects: 74
Study 1786954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 7138048 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% anthralin combined with UV-B therapy
Number of subjects: 9
Study 7138048 — intervention group
Group type: COMPARATOR
Intervention: 0.01% anthralin combined with UV-B therapy
Number of subjects: 9
Study 30302940 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital administration of ticagrelor
Number of subjects: 1630
Study 30302940 — intervention group
Group type: COMPARATOR
Intervention: In-hospital administration of ticagrelor
Number of subjects: 1630
Study 30302940 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 1630
Study 30029204 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Metronome (IM) training, 35-40 min per session, twice a week for 6 weeks
Number of subjects: 20
Study 30029204 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 30029204 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Metronome (IM) training
Number of subjects: 20
Study 26865039 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 456
Study 26865039 — intervention group
Group type: COMPARATOR
Intervention: Lower Extremity Training (LET)
Number of subjects: 456
Study 24144243 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light and melatonin capsules
Number of subjects: 40
Study 24144243 — intervention group
Group type: COMPARATOR
Intervention: Dim light and melatonin capsules
Number of subjects: 40
Study 24144243 — intervention group
Group type: COMPARATOR
Intervention: Bright light and placebo capsules
Number of subjects: 40
Study 24144243 — intervention group
Group type: COMPARATOR
Intervention: Dim light and placebo capsules
Number of subjects: 40
Study 22128084 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 311
Study 19463608 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative statin treatment
Number of subjects: 2152
Study 19463608 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment (control)
Number of subjects: 2152
Study 17660640 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chloral hydrate (40 mg/kg)
Number of subjects: 20
Study 17660640 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 20
Study 17660640 — intervention group
Group type: COMPARATOR
Intervention: Placebo session
Number of subjects: 20
Study 17660640 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drug regimens (chloral hydrate and diazepam)
Number of subjects: 20
Study 15295362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin monohydrate macrocrystals
Number of subjects: 449
Study 15295362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 11598383 — intervention group
Group type: EXPERIMENTAL
Intervention: High insulin (15 mU/kg x min)
Number of subjects: 0
Study 11598383 — intervention group
Group type: COMPARATOR
Intervention: Low insulin (1.5 mU/kg x min)
Number of subjects: 0
Study 9594683 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 supplementation with isoniazid therapy
Number of subjects: 85
Study 9594683 — intervention group
Group type: COMPARATOR
Intervention: Placebo with isoniazid therapy
Number of subjects: 85
Study 7988298 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-glucose infusion
Number of subjects: 327
Study 7988298 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 327
Study 2660054 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroid treatment
Number of subjects: 20
Study 2660054 — intervention group
Group type: COMPARATOR
Intervention: Natural allergen exposure
Number of subjects: 20
Study 31023428 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of 6 or 7 risk factors
Number of subjects: 690
Study 31023428 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of 3 to 7 risk factors
Number of subjects: 690
Study 31023428 — intervention group
Group type: EXPERIMENTAL
Intervention: No smoking, regular physical activity, dietary adherence, A1c <7%
Number of subjects: 690
Study 31023428 — intervention group
Group type: COMPARATOR
Intervention: 0 to 1 controlled risk factors
Number of subjects: 690
Study 28867497 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg
Number of subjects: 631
Study 28867497 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg
Number of subjects: 631
Study 28867497 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir, emtricitabine, and tenofovir alafenamide
Number of subjects: 631
Study 28867497 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir, abacavir, and lamivudine
Number of subjects: 631
Study 25487355 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV) added to peginterferon and ribavirin (PR)
Number of subjects: 1161
Study 25487355 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) added to peginterferon and ribavirin (PR)
Number of subjects: 1161
Study 24245929 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI without LOC (n = 53)
Number of subjects: 127
Study 24245929 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI with LOC (n = 35)
Number of subjects: 127
Study 24245929 — intervention group
Group type: COMPARATOR
Intervention: no-TBI (n = 39)
Number of subjects: 127
Study 24245929 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD and depression symptoms
Number of subjects: 127
Study 23038220 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (Dar), cumulative dose 11.1 µg/kg b.w. over 8 months
Number of subjects: 63
Study 23038220 — intervention group
Group type: COMPARATOR
Intervention: Control group (Co)
Number of subjects: 63
Study 23038220 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (Dar)
Number of subjects: 63
Study 19239712 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 984
Study 19239712 — intervention group
Group type: COMPARATOR
Intervention: Vaginal placebo
Number of subjects: 984
Study 17519150 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended oral contraceptive regimen containing 3 mg drosperinone and 30 microg ethinyl estradiol
Number of subjects: 111
Study 17519150 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day hormone-free interval (HFI)
Number of subjects: 111
Study 17519150 — intervention group
Group type: COMPARATOR
Intervention: 21/7 cycle
Number of subjects: 111
Study 15593360 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 342
Study 12414848 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with daily injections of 0.4 mg GH/d (group A)
Number of subjects: 29
Study 12414848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment with 0.8 mg GH/d for 14 days every 3 months (group B)
Number of subjects: 29
Study 12414848 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (A and B)
Number of subjects: 29
Study 9884268 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFR:Fc 1 hr before OKT3 on days 0 and 3
Number of subjects: 16
Study 9884268 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFR:Fc
Number of subjects: 16
Study 9884268 — intervention group
Group type: COMPARATOR
Intervention: Control (no TNFR:Fc)
Number of subjects: 16
Study 8681976 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of aminoglycosides
Number of subjects: 3181
Study 1695801 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy group (89 patients) received Vincristine (1.5 mg/m2), Bleomycin (15 mg), Methotrexate (80 mg)
Number of subjects: 226
Study 1695801 — intervention group
Group type: COMPARATOR
Intervention: Control group (98 patients) underwent the same surgical procedure
Number of subjects: 226
Study 1695801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (chemotherapy and control)
Number of subjects: 226
Study 356761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent levamisole therapy (150 mg daily for 3 days of each week)
Number of subjects: 0
Study 356761 — intervention group
Group type: COMPARATOR
Intervention: Continuous levamisole therapy (150 mg daily)
Number of subjects: 0
Study 31761933 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric TB treatment
Number of subjects: 850
Study 31761933 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 850
Study 30602450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic altering stimuli (DAS) video viewing for 30 minutes using ReviView
Number of subjects: 35
Study 26776321 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial evidence-based booklet
Number of subjects: 129
Study 26776321 — intervention group
Group type: COMPARATOR
Intervention: Biomedical-based booklet (Control)
Number of subjects: 129
Study 25940331 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraspan™ 10 mL kg⁻¹ for preloading and 0.9% saline for maintenance until six hours from the end of preloading
Number of subjects: 160
Study 25940331 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline for preloading and maintenance until six hours from the end of preloading
Number of subjects: 160
Study 23054528 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental video educational program
Number of subjects: 474
Study 23054528 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture series (Control)
Number of subjects: 474
Study 22055892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS)
Number of subjects: 110
Study 22055892 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release morphine sulfate (IRMS)
Number of subjects: 110
Study 19377050 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine 4 microg/mL with bupivacaine 1.25 mg/mL by patient-controlled epidural analgesia
Number of subjects: 52
Study 19377050 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 1.25 mg/mL alone
Number of subjects: 52
Study 16342193 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G‐CSF, 5 microg/kg/day) administered subcutaneously for 5 days for mobilization of CD34(+) cells.
Number of subjects: 9
Study 16342193 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of peripheral blood progenitor cells (PBPCs) on day 5 after G‐CSF administration.
Number of subjects: 9
Study 16342193 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF mobilization of CD34(+) cells.
Number of subjects: 9
Study 15515749 — intervention group
Group type: EXPERIMENTAL
Intervention: Three‐phase bone scintigraphy using Tc‐99m‐MDP
Number of subjects: 32
Study 10542895 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml 6% HES 200/0.62 (30 g)
Number of subjects: 0
Study 10542895 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml 10% HES 200/0.5
Number of subjects: 0
Study 10542895 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200/0.62
Number of subjects: 0
Study 10542895 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200/0.5
Number of subjects: 0
Study 7498231 — intervention group
Group type: EXPERIMENTAL
Intervention: [123I]beta‐CIT‐FE
Number of subjects: 4
Study 7498231 — intervention group
Group type: COMPARATOR
Intervention: [123I]beta‐CIT
Number of subjects: 4
Study 7498231 — intervention group
Group type: COMPARATOR
Intervention: [123I]beta‐CIT‐FP
Number of subjects: 4
Study 2312773 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg atenolol
Number of subjects: 12
Study 2312773 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol CR/ZOK
Number of subjects: 12
Study 2312773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7010383 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg cefaclor 3‐times daily (intermittent)
Number of subjects: 298
Study 7010383 — intervention group
Group type: COMPARATOR
Intervention: 500 mg amoxycillin 3‐times daily (continuous)
Number of subjects: 298
Study 31525129 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw almonds (1.5 oz twice daily)
Number of subjects: 33
Study 31525129 — intervention group
Group type: COMPARATOR
Intervention: CHO-based foods (isocaloric)
Number of subjects: 33
Study 30896743 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake (mean 886 mg/day)
Number of subjects: 1994
Study 30896743 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1994
Study 30896743 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 1994
Study 27400927 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin
Number of subjects: 80
Study 27400927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27400927 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine withdrawal (both groups)
Number of subjects: 80
Study 25119374 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-management intervention with interactive sections (8 weeks)
Number of subjects: 51
Study 25119374 — intervention group
Group type: COMPARATOR
Intervention: Control group (denied access to interactive sections)
Number of subjects: 51
Study 23164097 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE-covered balloon-expandable stents
Number of subjects: 174
Study 23164097 — intervention group
Group type: COMPARATOR
Intervention: Uncovered balloon-expandable stents
Number of subjects: 174
Study 19879131 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and Tamoxifen for 2 years
Number of subjects: 347
Study 19879131 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy only
Number of subjects: 347
Study 19879131 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen only
Number of subjects: 347
Study 19879131 — intervention group
Group type: COMPARATOR
Intervention: BCS only (Control)
Number of subjects: 347
Study 17964983 — intervention group
Group type: EXPERIMENTAL
Intervention: Dworak grade 2 MDC (n = 19)
Number of subjects: 56
Study 17964983 — intervention group
Group type: EXPERIMENTAL
Intervention: Dworak grade 1 MDC (n = 37)
Number of subjects: 56